AstraZeneca boosts cardiovascular-drug pipeline with AlphaCore buy

04/4/2013 | Reuters · American City Business Journals

AstraZeneca's MedImmune unit agreed to purchase AlphaCore Pharma, a privately held U.S. biotechnology firm, for an undisclosed amount. The acquisition gives AstraZeneca access to AlphaCore's ACP-501, a cholesterol-lowering drug candidate intended to reduce the risk of heart attack and stroke. The deal is expected to strengthen AstraZeneca's early-stage cardiovascular-drug pipeline.

View Full Article in:

Reuters · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ